Block Grant R41AG029768

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), is supporting the evaluation of the safety, tolerability, and immunogenicity of an adjuvanted preventive dual AB/Tau vaccine, DUVAX, in healthy volunteers. The $499,754 award to Nuravax, Inc. will fund a Phase 1 study to investigate this novel Alzheimer's disease (AD) vaccine candidate that aims to inhibit both amyloid-beta (AB) and pathological tau aggregation,...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $356,174 to The Regents of the University of California, San Francisco (UCSF) to conduct in vivo testing of structure-based vaccine candidates targeting Alzheimer's disease. The goal is to determine the efficacy of an active immunization strategy in preserving cognitive and neural function by slowing the formation of amyloid-beta or tau protein aggregation in the brain. The research will use...

Federal Grant Award Summary The University of Pittsburgh received a $433,710 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded February 15, 2026, with completion targeted for January 31, 2028. The grant funds development and refinement of a novel replication-defective herpes simplex virus (RDHSV) vector platform designed as a gene therapy treatment for Alzheimer's disease. The RDHSV vector platform delivers multiple therapeutic genes simultaneously,...

This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $156,000 to Thomas Jefferson University, doing business as Sidney Kimmel Medical College, to develop novel therapeutic strategies for suppressing the cGAS-STING pathway in Alzheimer's disease (AD). The project aims to generate intrabodies to neutralize RNA::DNA hybrids that activate the cGAS-STING pathway, leading to neuroinflammation and neuronal death in AD cell models....

Federal Grant Award Summary Aivocode, Inc. received a $1.24M Phase II Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop single domain antibodies targeting Connective Tissue Growth Factor (CTGF) as a therapeutic intervention for Alzheimer's disease (AD). The award, effective September 20, 2025 through May 31, 2027, supports preclinical research and development activities designed to test CTGF-neutralizing antibodies in mouse models of...

Summary The National Institute on Aging awarded Weill Medical College of Cornell University a Cooperative Agreement valued at $3,252,734 under the Aging Research program (CFDA 93.866) effective April 1, 2026 through March 31, 2028. This award supports Phase 1A clinical trial development and execution for a novel gene therapy targeting Apolipoprotein E4 (APOE4) homozygous Alzheimer's disease patients. The primary deliverables include conducting a Phase 1A safety and dose-ranging clinical trial...

Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded $9.78 million to the Institute For Molecular Medicine Inc. under the Aging Research program (CFDA 93.866) on August 1, 2025, to conduct a multicenter Phase 1 clinical trial evaluating the safety and immunogenicity of AV-1980R/A, a preventive tau vaccine for Alzheimer's disease (AD). The project, which runs through July 31, 2030, addresses the current paradigm shift in AD research from treatment to prevention by...

Glial Therapeutics, LLC received a $254,896 Phase I Small Business Technology Transfer (STTR) award from the National Institute on Aging under the Aging Research program (CFDA 93.866) for the period September 20, 2025 through May 31, 2027. The company will conduct preclinical and translational research to evaluate the safety and efficacy of ADWA11, a humanized monoclonal antibody targeting the αvβ8 integrin, as a potential therapeutic intervention for Alzheimer's disease (AD). The research...

Federal Grant Award Summary The National Institute on Aging (NIA) awarded a $1.08 million Project Grant to The Johns Hopkins University on August 1, 2025, under the Aging Research program (CFDA 93.866) to develop adeno-associated virus (AAV) vectors for selective manipulation of oligodendrocyte precursor cells (OPCs). The two-year project, concluding July 31, 2027, will generate novel OPC-selective AAV vectors and utilize them to investigate whether reactive transformation of OPCs surrounding...

This Project Grant award of $1,000,000, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Brigham & Women's Hospital to develop a precision nonviral brain delivery system for CD33-targeting siRNA to treat Alzheimer's disease. The research, conducted in collaboration with Massachusetts General Hospital, aims to characterize novel nanoparticles for efficient delivery of CD33 siRNA to microglia in the brain,...